Oncology Partnering Terms and Agreements -





The Oncology Partnering Terms and Agreements report provides comprehensive understanding and unprecedented access to the oncology partnering deals and agreements entered into by the worlds leading healthcare companies.

 

  • Trends in oncology partnering deals
  • Average deal terms for headline, upfront and royalty by stage of development
  • Oncology partnering agreement structure
  • Oncology partnering contract documents
  • Top oncology deals by value
  • Most active oncology dealmakers

 

The Oncology Partnering Terms and Agreements report provides comprehensive understanding and unprecedented access to the oncology partnering deals and agreements entered into by the worlds leading healthcare companies.

 

The report provides a detailed understanding and analysis of how and why companies enter oncology partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors oncology technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

 

Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases do not.

 

This report contains over 2,700 links to online copies of actual oncology deals and contract documents as submitted to the Securities Exchange Commission by companies and their partners. Contract documents provide the answers to numerous questions about a prospective partner’s flexibility on a wide range of important issues, many of which will have a significant impact on each party’s ability to derive value from the deal.

 

The initial chapters of this report provide an orientation of oncology dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in oncology dealmaking since 2009, including details of average headline, upfront, milestone and royalty terms.

 

Chapter 3 provides a review of the leading oncology deals since 2009. Deals are listed by headline value, signed by bigpharma, most active bigpharma, and most active of all biopharma companies. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

 

Chapter 4 provides a comprehensive listing of the top 50 bigpharma companies with a brief summary followed by a comprehensive listing of oncology deals, as well as contract documents available in the public domain. Where available, each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.

 

Chapter 5 provides a comprehensive and detailed review of oncology partnering deals signed and announced since 2009, where a contract document is available in the public domain. The chapter is organized by stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc), technology type and specific therapy focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

 

The report also includes numerous tables and figures that illustrate the trends and activities in oncology partnering and dealmaking since 2009.

 

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of oncology technologies and products.

 

Report scope 

 

Oncology Partnering Terms and Agreements is intended to provide the reader with an in-depth understanding and access to oncology trends and structure of deals entered into by leading companies worldwide.

 

Oncology Partnering Terms and Agreements includes:

 

  • Trends in oncology dealmaking in the biopharma industry since 2009
  • Analysis of oncology deal structure
  • Access to headline, upfront, milestone and royalty data
  • Case studies of real-life oncology deals
  • Access to over 2,700 oncology contract documents
  • The leading oncology deals by value since 2009
  • Most active oncology dealmakers since 2009
  • The leading oncology partnering resources

 

In Oncology Partnering Terms and Agreements, the available contracts are listed by:

 

  • Headline value
  • Upfront payment value
  • Royalty rate value
  • Stage of development at signing
  • Deal component type
  • Technology type
  • Specific therapy indication

 

Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

 

The Oncology Partnering Terms and Agreements report provides comprehensive access to available deals and contract documents for over 2,700 oncology deals. Analyzing actual contract agreements allows assessment of the following:

 

  • What are the precise oncology rights granted or optioned?
  • What is actually granted by the agreement to the partner company?
  • What exclusivity is granted?
  • What is the payment structure for the deal?
  • How are sales and payments audited?
  • What is the deal term?
  • How are the key terms of the agreement defined?
  • How are IPRs handled and owned?
  • Who is responsible for commercialization?
  • Who is responsible for development, supply, and manufacture?
  • How is confidentiality and publication managed?
  • How are disputes to be resolved?
  • Under what conditions can the deal be terminated?
  • What happens when there is a change of ownership?
  • What sublicensing and subcontracting provisions have been agreed?
  • Which boilerplate clauses does the company insist upon?
  • Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
  • Which jurisdiction does the company insist upon for agreement law?

 

Oncology Partnering Terms and Agreements provides the reader with the following key benefits:

 

  • In-depth understanding of oncology deal trends since 2009
  • Access to headline, upfront, milestone and royalty data
  • Comprehensive access to over 2,700 actual oncology contracts entered into by the world’s biopharma companies
  • Detailed access to actual oncology contracts enter into by the leading fifty bigpharma companies
  • Insight into the terms included in a oncology agreement, together with real world clause examples
  • Understand the key deal terms companies have agreed in previous deals
  • Undertake due diligence to assess suitability of your proposed deal terms for partner companies

 

Chapter 1 – Introduction 

  

Chapter 2 – Trends in oncology dealmaking 

 

2.1. Introduction           

2.2. Oncology partnering over the years           

2.3. Bigpharma oncology dealmaking activity    

2.4. Bigpharma not active in oncology  

2.5. Oncology partnering by deal type   

2.6. Oncology partnering by industry sector

2.7. Oncology partnering by stage of development

2.8. Oncology partnering by technology type    

2.9. Oncology partnering by oncology indication

2.10. Average deal terms for oncology  

2.10.1 Oncology headline values          

2.10.2 Oncology upfront payments       

2.10.3 Oncology milestone payments   

2.10.4 Oncology royalty rates

 

Chapter 3 – Leading oncology deals 

 

3.1. Introduction           

3.2. Top oncology deals by value         

3.3. Top oncology deals involving bigpharma

 

Chapter 4 – Bigpharma oncology deals 

                                         

4.1. Introduction

4.2. How to use bigpharma partnering deals      

4.3. Bigpharma oncology partnering company profiles   

Abbott 

Actavis

Actelion           

Allergan           

Amgen

Aspen Pharmacare      

Astellas           

AstraZeneca    

Baxter International

Bayer  

Biogen Idec     

Boehringer Ingelheim   

Bristol-Myers Squibb   

Celgene           

CSL     

Daiichi Sankyo

Dainippon Sumitomo

Eisai

Eli Lilly

Endo Pharmaceuticals

Galderma        

Gilead Sciences           

GlaxoSmithKline          

Grifols 

Hospira

Johnson & Johnson

Kyowa Hakko Kirin

Lundbeck         

Menarini          

Merck & Co     

Merck KGaA    

Mitsubishi Tanabe

Novartis          

Novo Nordisk

Otsuka

Pfizer  

Purdue

Roche 

Sanofi  

Servier

Takeda

Teva   

Valeant

Watson

 

Chapter 5 – Oncology partnering contracts directory 

 

5.1. Introduction           

5.2. By deal type

Asset purchase

Assignment     

Bigpharma outlicensing

Co-development

Collaborative R&D

Co-market

Contract service

Co-promotion   

CRADA

Cross-licensing

Development   

Distribution      

Equity purchase           

Evaluation       

Grant   

Joint venture    

Licensing         

Litigation         

Loan    

Manufacturing  

Marketing        

Material transfer

Option 

Promotion        

Research         

Royalty financing

Settlement       

Spin out           

Sub-license     

Supply 

Technology transfer     

Termination     

Warranty         

5.3. By stage of development

Discovery        

Preclinical       

Phase I

Phase II           

Phase III          

Regulatory       

Marketed         

Formulation

5.4. By technology type

Analysis          

Animal models 

Antibodies       

Assays

Bioinformatics  

Biological compounds  

Biomarkers      

Cell therapy     

Clinical testing

Diagnostic - companion

Devices           

Diagnostics     

Discovery tools

Drug delivery   

Enabling technology

Enviromental   

Epigenetics     

Equipment       

Facilities          

Gene therapy   

Genomics        

Imaging           

Implant

Industrial chemicals     

In vitro models 

Nanotechnology           

Natural product

Oligonucleotide

Orphan drug    

Peptides          

Personalised medicine

Pharmacogenomics

Processes       

Proteomics

Radio/Chemo-therapy

Recombinant DNA       

Research services       

Research supplies       

RNA therapeutics         

Screening        

Small molecules          

Software tools  

Stem cells       

Vaccines

 

Chapter 6 – Oncology dealmaking by indication 

 

6.1. Introduction           

6.2. Deals by therapeutic indication      

Oncology         

Adenocarcinoma          

Basal cell carcinoma    

Bile duct cancer           

Bladder cancer

Bone cancer    

Brain cancer    

Breast cancer  

Cervical cancer

Colorectal cancer         

Endometrial     

Esophageal cancer

Gastric cancer 

Head and neck cancer 

Kaposi's sarcoma        

Kidney cancer  

Leukemia

Acute lymphoblastic leukemia

Acute myelogenous leukemia

Chronic lymphocytic leukemia  

Chronic myelogenous leukemia

Liver cancer    

Lung cancer    

Non small cell lung cancer       

Small cell lung cancer  

Lymphoma       

Hodgkin's lymphoma    

Non Hodgkin's lymphoma         

Melanoma        

Mesothelioma  

Metastases      

Bone metastases         

Multiple myeloma

Neuroblastoma

Ovarian cancer

Pancreatic cancer

Prostate cancer           

Renal cell carcinoma    

Sarcoma

Non-melanoma skin cancer

Solid tumors    

Symptoms       

Alopecia          

Cachexia         

Cancer pain     

Neuropathic     

Chemotherapy 

Dysphagia       

Lymphoedema 

Nausea

Oral mucositis 

Radiotherapy   

Vomiting          

Testicular cancer         

Thyroid cancer

 

Chapter 7 – Partnering resource center 

 

7.1. Online partnering   

7.2. Partnering events  

7.3. Further reading on dealmaking

           

About Wildwood Ventures      

 

Current Partnering

Current Agreements     

Recent titles from CurrentPartnering

Order Form – Reports  

Order Form – Therapy Reports 

 

Appendices 

 

Appendix 1 – Directory of oncology deals by company A-Z 2009-2014

Appendix 2 – Directory of oncology deals by deal type 2007-20123         

Appendix 3 – Directory of oncology deals by stage of development 2009-2014 

Appendix 4 – Directory of oncology deals by technology type 2009-2014

Appendix 5 – Deal type definitions        

  

Table of figures 

 

Figure 1: Oncology partnering since 2009         

Figure 2: Bigpharma – top 50 – Oncology deals 2009 to 2014

Figure 3: Bigpharma oncology deal frequency – 2009 to 2014

Figure 4: Inactive bigpharma in oncology 2009-2014    

Figure 5: Oncology partnering by deal type since 2009  

Figure 6: Oncology partnering by industry sector since 2009

Figure 7: Oncology partnering by stage of development since 2009

Figure 8: Oncology partnering by technology type since 2009   

Figure 9: Oncology partnering by oncology target since 2009    

Figure 10: Oncology deals with a headline value           

Figure 11: Oncology deal headline value distribution, US$million – discovery stage

Figure 12: Oncology deal headline value distribution, US$million – preclinical stage

Figure 13: Oncology deal headline value distribution, US$million – phase I stage

Figure 14: Oncology deal headline value distribution, US$million – phase II stage

Figure 15: Oncology deal headline value distribution, US$million – phase III stage

Figure 16: Oncology deal headline value distribution, US$million – regulatory stage

Figure 17: Oncology deal headline value distribution, US$million – marketed stage

Figure 18: Summary median headline value by stage of development, 2009-2014

Figure 19 Oncology deals with upfront payment values

Figure 20: Oncology deal upfront payment distribution, US$million – discovery stage

Figure 21: Oncology deal upfront payment distribution, US$million – preclinical stage

Figure 22: Oncology deal upfront payment distribution, US$million – phase I stage

Figure 23: Oncology deal upfront payment distribution, US$million – phase II stage

Figure 24: Oncology deal upfront payment distribution, US$million – phase III stage

Figure 25: Oncology deal upfront payment distribution, US$million – regulatory stage

Figure 26: Oncology deal upfront payment distribution, US$million – marketed stage

Figure 27: Summary median upfront payments by stage of development, 2009-2014

Figure 28: Oncology deals with milestone payments

Figure 29: Oncology deal milestone distribution, US$million – discovery stage   

Figure 30: Oncology deal milestone distribution, US$million – preclinical stage  

Figure 31: Oncology deal milestone distribution, US$million – phase I stage      

Figure 32: Oncology deal milestone distribution, US$million – phase II stage     

Figure 33: Oncology deal milestone distribution, US$million – phase III stage    

Figure 34: Oncology deal milestone distribution, US$million – regulatory stage  

Figure 35: Oncology deal milestone distribution, US$million – marketed stage   

Figure 36: Oncology deals with royalty rates, %

Figure 37: Oncology deal royalty rate distribution, US$million – discovery stage

Figure 38: Oncology deal royalty rate distribution, US$million – preclinical stage

Figure 39: Oncology deal royalty rate distribution, US$million – phase I stage    

Figure 40: Oncology deal royalty rate distribution, US$million – phase II stage

Figure 41: Oncology deal royalty rate distribution, US$million – phase III stage

Figure 42: Oncology deal royalty rate distribution, US$million – regulatory stage

Figure 44: Summary median royalty rate by stage of development, 2009-2014

Figure 45: Top oncology deals by value since 2009

Figure 46: Top oncology deals signed by bigpharma value since 2009

Figure 47: Online partnering resources 

Figure 48: Forthcoming partnering events